Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

National Center for Cardiovascular Diseases

Status: Enrolling

Conditions: Ventricular Thrombus

Treatments: Other: non-antithrombotic therapy; Drug: antiplatelet agents; Drug: non-vitamin K antagonist oral anticoagulants (NOACs); Drug: vitamin K antagonists (VKAs)

Study type: Observational

Funder types: Other

Identifiers

NCT05006677

2021-TR

Details and patient eligibility

About

To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT.

Enrollment: 480 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with ventricular thrombus(VT), regardless of sex, basic diseases, occupation or education;
• The VT should be found newly within 3 months;
• The observational phase should last until the time that patients who had achieved thrombus resolution. The following up period after the phase ended should continue for at least 3 months.

Exclusion criteria

• Individuals received standard antithrombotic therapy within 4 weeks;
• Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the VT was found in the first time;
• Had a long history of VT more than three months.

Trial design

480 participants in 4 patient groups

non-vitamin K antagonist oral anticoagulants (NOACs)

Treatment:

Drug: non-vitamin K antagonist oral anticoagulants (NOACs)

vitamin K antagonists (VKAs)

Treatment:

Drug: vitamin K antagonists (VKAs)

antiplatelet agents

Treatment:

Drug: antiplatelet agents

non-antithrombotic therapy

Treatment:

Other: non-antithrombotic therapy